Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

Allan Z Iversen; Soeren Galatius; Sune Ammentorp Haahr-Pedersen; Jan K Madsen; Jan S Jensen

doi:10.2165/11587170-000000000-00000

Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

Allan Z Iversen, Soeren Galatius, Sune Ammentorp Haahr-Pedersen, Jan K Madsen, Jan S Jensen

3 Citationer (Scopus)

Abstract

Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged

Originalsprog	Engelsk
Tidsskrift	Drugs & Aging
Vol/bind	28
Udgave nummer	5
Sider (fra-til)	369-78
Antal sider	10
ISSN	1170-229X
DOI	https://doi.org/10.2165/11587170-000000000-00000
Status	Udgivet - 1 maj 2011

Adgang til dokumentet

10.2165/11587170-000000000-00000

Andre filer og links

Link to publication in Scopus

Citationsformater

Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study. / Iversen, Allan Z ; Galatius, Soeren; Haahr-Pedersen, Sune Ammentorp et al.
I: Drugs & Aging, Bind 28, Nr. 5, 01.05.2011, s. 369-78.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{d4c572defe954a87bf71faabdcb71ce3,

title = "Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study",

abstract = "Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged ",

author = "Iversen, \{Allan Z\} and Soeren Galatius and Haahr-Pedersen, \{Sune Ammentorp\} and Madsen, \{Jan K\} and Jensen, \{Jan S\}",

year = "2011",

month = may,

day = "1",

doi = "10.2165/11587170-000000000-00000",

language = "English",

volume = "28",

pages = "369--78",

journal = "Drugs \& Aging",

issn = "1170-229X",

publisher = "Adis",

number = "5",

}

TY - JOUR

T1 - Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

AU - Iversen, Allan Z

AU - Galatius, Soeren

AU - Haahr-Pedersen, Sune Ammentorp

AU - Madsen, Jan K

AU - Jensen, Jan S

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged

AB - Background: An increasing proportion of patients with acute coronary syndrome (ACS) requiring percutaneous coronary intervention (PCI) are classified as elderly (aged ≥70 years). The glycoprotein IIb/IIIa inhibitor abciximab is known to reduce adverse outcomes in patients aged

UR - https://www.scopus.com/pages/publications/79955696682

U2 - 10.2165/11587170-000000000-00000

DO - 10.2165/11587170-000000000-00000

M3 - Journal article

C2 - 21542659

SN - 1170-229X

VL - 28

SP - 369

EP - 378

JO - Drugs & Aging

JF - Drugs & Aging

IS - 5

ER -

Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater